Epizyme, Inc., 325 Vassar St., Cambridge, MA 02139, USA.
FEBS Lett. 2011 Oct 3;585(19):3011-4. doi: 10.1016/j.febslet.2011.08.018. Epub 2011 Aug 17.
Mutations at tyrosine 641 (Y641F, Y641N, Y641S and Y641H) in the SET domain of EZH2 have been identified in patients with certain subtypes of non-Hodgkin lymphoma (NHL). These mutations were shown to change the substrate specificity of EZH2 for various methylation states of lysine 27 on histone H3 (H3K27). An additional mutation at EZH2 Y641 to cysteine (Y641C) was also found in one patient with NHL and in SKM-1 cells derived from a patient with myelodisplastic syndrome (MDS). The Y641C mutation has been reported to dramatically reduce enzymatic activity. Here, we demonstrate that while the Y641C mutation ablates enzymatic activity against unmethylated and monomethylated H3K27, it is superior to wild-type in catalyzing the formation of trimethylated H3K27 from the dimethylated precursor.
EZH2 SET 结构域中的酪氨酸 641 发生突变(Y641F、Y641N、Y641S 和 Y641H),已在某些非霍奇金淋巴瘤(NHL)患者中被发现。这些突变改变了 EZH2 对组蛋白 H3 赖氨酸 27 各种甲基化状态(H3K27)的底物特异性。在一位 NHL 患者和一位骨髓增生异常综合征(MDS)患者衍生的 SKM-1 细胞中,还发现了 EZH2 Y641 突变为半胱氨酸(Y641C)。据报道,Y641C 突变极大地降低了酶活性。在这里,我们证明,虽然 Y641C 突变使未甲基化和单甲基化 H3K27 的酶活性失活,但它比野生型更能催化从二甲基化前体形成三甲基化 H3K27。